Gilder Gagnon Howe & Co’s BioCryst Pharmaceuticals BCRX Stock Holding History

Gilder Gagnon Howe & Co’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-303,642	Closed	-$3.83M	–	248
2022 Q3	$3.83M	Sell	303,642 -1,515	-0.5%	-$19.5K	0.07%	147
2022 Q2	$3.23M	Sell	305,157 -33,852	-10%	-$349K	0.06%	158
2022 Q1	$5.51M	Sell	339,009 -1,770	-0.5%	-$28.4K	0.05%	172
2021 Q4	$4.72M	Buy	340,779 +26,973	+9%	+$357K	0.03%	221
2021 Q3	$4.51M	Buy	313,806 +413	+0.1%	+$6.51K	0.02%	258
2021 Q2	$4.96M	Buy	313,393 +101,986	+48%	+$1.39M	0.02%	259
2021 Q1	$2.15M	Buy	+211,407	New	+$2.18M	0.01%	276
2020 Q4	–	Sell	-592,200	Closed	-$2.03M	–	339
2020 Q3	$2.03M	Buy	+592,200	New	+$2.54M	0.01%	238

Other funds holding BCRX

AWA

Arete Wealth Advisors Chicago, Illinois $1.33B AUM 25.12% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

RP Management New York $139M AUM 37.98% 1-Year Est. Return

Gilder Gagnon Howe & Co's BCRX Position: Q4 2022 in Review

Gilder Gagnon Howe & Co sold out of BioCryst Pharmaceuticals (BCRX) in Q4 2022, closing a stake of 303,642 shares — an estimated $3.83M sold.

Gilder Gagnon Howe & Co first reported a position in BCRX in Q3 2020 and held it in 8 quarters. The position peaked at $5.51M in Q1 2022. 230 funds tracked by Wall St. Rank hold BCRX as of Q4 2022.

Gilder Gagnon Howe & Co reported no remaining BioCryst Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
Gilder Gagnon Howe & Co sold 303,642 BioCryst Pharmaceuticals shares in Q4 2022, an estimated $3.83M.
Gilder Gagnon Howe & Co first reported a position in BioCryst Pharmaceuticals in Q3 2020 and held it in 8 quarters.
Gilder Gagnon Howe & Co's BioCryst Pharmaceuticals position peaked at $5.51M in Q1 2022.
230 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q4 2022.

Based on Gilder Gagnon Howe & Co's 13F filing for Q4 2022, filed 14 Feb 2023.